



1Q26 **Earnings Presentation**

April 29, 2026

Disclaimer

Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its continued access to capital to fund its business plan. These forward-looking statements substantially depend on the market conditions, government regulations, competitive pressures, the performance of the Brazilian economy and the industry, among other factors, as well as the risks shown in our filed disclosure documents, and are therefore subject to change without prior notice.

In addition, unaudited information herein reflects management's interpretation of information taken from its financial statements and their respective adjustments, which were prepared in accordance with market practices and for the sole purpose of a more detailed and specific analysis of our results. Therefore, these additional considerations and data must also be analyzed and interpreted independently by shareholders and market agents, who should carry out their own analysis and draw their own conclusions from the information reported herein. No data or interpretative analysis provided by our management should be treated as a guarantee of future performance or results and are merely illustrative of our directors' vision of our results.

The management is not responsible for compliance or accuracy of the data from this report, which must be considered as for informational purposes only, and should not override the analysis of our audited consolidated financial statements for purposes of a decision to invest in our stock, or for any other purpose.

1Q26 Highlights

- **9.4%** INCREASE IN PHARMACEUTICAL RETAIL SELL-OUT¹
+1.5 PERCENTAGE POINT ABOVE THE MARKET GROWTH IN THE CATEGORIES IN WHICH THE COMPANY OPERATES
- PROGRESS IN KEY DISTRIBUTION AND LOGISTICS INDICATORS
OTIF (On-Time In-Full): **+12 PERCENTAGE POINTS²**
OCT (Order Cycle Time): **+14%²**
- PRIVATE CAPITAL RAISING
CASH INFLOW OF **R\$ 1.5 BILLION**
18%³ REDUCTION IN NET DEBT

REDUCED RISKS ASSOCIATED WITH CREDIT MARKET VOLATILITY
REDUCED INTEREST EXPENSES
INCREASED INVESTMENT CAPACITY


Note: (1) Sell-out PPP (Pharmacy Purchase Price), according to IQVIA; (2) Q1 2026 vs. Q1 2025; (3) March 30, 2025 vs. December 31, 2025

1Q26 Results (R\$ million)



- > **NET REVENUE**
R\$ 2,017.8 +86.7%¹
- > **GROSS MARGIN**
60.0%³ +1,280bps⁴
- > **MARKETING EXPENSES**
R\$ 335.8 -8.6%¹
- > **SELLING EXPENSES**
R\$ 269.4 +2.7%¹
- > **GENERAL AND ADMINISTRATIVE EXPENSES**
R\$ 98.1 +13.9%¹
- > **EBITDA FROM CONTINUING OPERATIONS**
R\$ 586.5 +R\$735,0⁴
- > **NET EARNINGS FROM CONTINUING OPERATIONS**
R\$ 345.7 +R\$484,5¹

1Q26 Cash Flow (R\$ million)



Note: **Cash Flow from Financing:** Includes receipts from issues and new financing and interest on financial investments; **PP&E:** includes purchase and sale of fixed assets; **EBITDA:** Considers the LTM EBITDA from Continuing Operations

